Transitioning from Antidepressants to Methylene Blue: A Gentle Shift

1. Why this transition?

Methylene blue acts as an antidepressant—but differently. It targets neuroinflammation, restores cellular respiration, and supports the nervous system. It doesn’t replace a chemical with another, but introduces a regenerative signal to the body.

This makes it possible to gradually move away from conventional treatment—while respecting the individual rhythm and sensitivity of the patient.

2. Misunderstood risks: clarifying serotonin syndrome

The rare alarming reports about methylene blue all concern intravenous high-dose use in hospital settings. The oral microdoses used in this context (< 0.4 mg/kg) do not lead to high plasma peaks and show no such side effects.

Below a certain threshold, methylene blue does not inhibit MAO-A and does not cause serotonin syndrome.

⚠️ This transition should never be attempted alone – it requires medical guidance and personalized support.

3. The three therapeutic phases

🔹 Phase 1: Stabilize

• Continue current antidepressant treatment
• Introduce methylene blue at a low oral dose (maximum 10-20 mg/day)
• Monitor sleep, anxiety, energy levels

🔹 Phase 2: Dynamize

• Gradually shift to dynamized microdoses (0.2 mg → 0.002 mg → 0.00002 mg)
• Prepared by succussion following the Hahnemannian method
• Fewer side effects, improved vitality

🔹 Phase 3: Support the withdrawal

• Very gradual reduction of the antidepressant—only if emotional stability is reached
• Ongoing support through the dynamized blue
• Deepening the therapeutic journey: body awareness, autonomy, new alignment

4. A word of encouragement

This transition is a real opportunity. It opens a new relationship with yourself, your health, and your inner balance.
You’re not just switching substances—you’re changing paradigms.

👉 Voir comment se fait la transition vers le bleu de méthylène chez les patients sous antidépresseur

👉 Wie der Übergang von Antidepressiva zu Methylenblau konkret begleitet werden kann

👉 See how the transition from antidepressants to methylene blue can be supported in practice